Gitnux/Report 2026

Bioengineering Industry Statistics

The global bioengineering market was estimated at $295.88 billion in 2025, explore the figures behind growth, companies and trends into 2033.
210Statistics
76Sources
11Sections
1Visuals
39mRead
Bioengineering Industry Statistics
Samuel NorbergWritten by Samuel Norberg·Fact-checked by Maya Johansson
Published
How this report is researched
01Editorial Scope

Gitnux editors write the brief first: the topic, the inclusion rules, and the frame for what belongs.

02Source Research

Agents search the published record and log every extracted figure back to the passage it came from.

Read our full methodology →

Search agents attach provenance to every extracted figure.

Next review: within 31 days

01 Industry overview

The bioengineering industry at a glance

The global bioengineering market was estimated at $295.88 billion in 2025 and is projected to expand rapidly through 2033, supported by biologics, diagnostics, gene therapies and AI-enabled development.

$295.88B[61]
Global market size, 2025
17.53%[61]
Forecast CAGR, 2026–2033
22,200[50]
U.S. employment, 2025
46[20]
Novel U.S. drugs approved, 2025
Market size
The global bioengineering market was estimated at $295.88 billion in 2025. The estimate covers applications including therapeutic development, diagnostics, pharmaceutical biotechnology and industrial biotechnology.[61]
Forecast & CAGR
The market is projected to reach $1.479 trillion by 2033, representing a 17.53% compound annual growth rate from 2026 to 2033. Growth is expected to be supported by personalized medicine, diagnostics automation and scalable biomanufacturing.[61]
Market share & regions
In 2025 life-sciences M&A value, the Americas accounted for 73% or $272 billion, compared with 17% for Europe, the Middle East and Africa and 10% for Asia-Pacific. These figures indicate that the Americas remain the leading capital and commercial center for the broader bioengineering ecosystem.[34]
Segmentation
Bioengineering is segmented across therapeutics and biologics, diagnostics, medical technologies, agricultural and industrial biotechnology, and enabling platforms such as AI, gene editing and biomanufacturing. Within the market estimate, applications include personalized medicine, automated diagnostics and pharmaceutical and industrial biotechnology.[61]
Key players & concentration
The industry includes large pharmaceutical and medical-technology companies alongside specialized biotechnology firms, research institutions and contract development and manufacturing organizations. Deal value is concentrated among large transactions: in 2025, the average life-sciences deal size was approximately $2.7 billion and the first quarter represented 36% of the year's $99.7 billion total tracked by EY.[21]
Trends, drivers & challenges
Key growth drivers include biologics, cell and gene therapies, AI-assisted research, personalized medicine and advanced manufacturing. Major constraints include tightened financing, patent expirations, regulatory uncertainty and high development risk; U.S. employment of bioengineers and biomedical engineers is nevertheless projected to grow 8% from 2025 to 2035.[50][21]
Consumer behavior & competition
Competition is increasingly focused on differentiated biologics, rare-disease therapies, oncology, immunology, metabolic disease and platform technologies. In 2025, 23 of the FDA's 46 novel drug approvals received orphan-drug designation, showing the importance of specialized products addressing small patient populations.[20]
M&A
Biopharma venture funding in the United States and Europe totaled $24 billion across 410 rounds in 2025, down 14% from 2024. By the third quarter of 2026, biopharma M&A value had reached $138.9 billion across 113 deals, already exceeding the $122.1 billion recorded in full-year 2025.[23][62]
Regulation
Regulatory approvals remain a central industry gatekeeper. In 2025, the FDA approved 46 novel drugs, including 12 biologics, and approved 18 biosimilars for 10 reference products; the agency also reported 87 Breakthrough Therapy designations in its Biologics Program by the end of fiscal 2025.[20]
Latest news
The latest available industry reports point to a stronger 2026 deal market: biopharma M&A reached $138.9 billion across 113 deals by the third quarter, while alliance activity increasingly targeted oncology, immunology, metabolic disease, AI-enabled development and advanced biologic platforms.[62][21]

02 Ranking

Top 10 Companies in the Bioengineering Industry

The leading companies in the bioengineering industry, ranked on market impact, performance, momentum, innovation and brand popularity.

Updated November 11, 2026 · Next review December 11, 2026

Verdict

Eli Lilly and Company stands out for biopharmaceutical medicines and biologics because it recorded revenue growth of 44.7% and an operating margin of 40.4% in 2025, while Boston Scientific focuses on minimally invasive devices since it makes devices for cardiovascular, endoscopy, urology and other fields with revenue growth of 19.9% in 2025.

Ranked by Overall score · How we score ↓

Editor's top 3 picks

Where to start, by need.

  1. #1 Overall · Leader in biopharmaceutical medicines

    Eli Lilly and Company

    US

    Ranked #1 · 9.6 · Biopharmaceutical medicines

    Why we picked it: It develops, manufactures and markets medicines using advanced biological research and engineering, with 2025 revenue growth of 44.7% and an operating margin of 40.4%.

    See in ranking ↓Visit lilly.com ↗

  2. Leader in minimally invasive devices

    Boston Scientific

    US

    Ranked #2 · 9.1 · Minimally invasive devices

    Why we picked it: It makes minimally invasive devices for cardiovascular, endoscopy, urology and other fields, with 2025 revenue growth of 19.9% and an operating margin of 18%.

    See in ranking ↓Visit bostonscientific.com ↗

  3. Leader in diagnostics and sequencing

    Roche

    CH

    Ranked #3 · 9.1 · Diagnostics and sequencing

    Why we picked it: It combines pharmaceuticals with global diagnostics and next-generation sequencing, backed by R&D at 19.8% of revenue in 2025.

    See in ranking ↓Visit roche.com ↗

Pick 1 is the #1 company overall. Picks 2 and 3 are the highest-ranked companies in the top 5 that add a new segment.

Full ranking

Sort by
Top 10 companies in the bioengineering industry, 2026 – Gitnux ranking
#CompanyOverall ↓Company snapshot
1

Eli Lilly and Company

Biopharmaceutical medicines · US

9.6
2

Boston Scientific

Minimally invasive devices · US

9.1
3

Roche

Diagnostics and sequencing · CH

9.1
4

Novo Nordisk

Biologic therapies · DK

9.0
5

Siemens Healthineers

Imaging and minimally invasive tech · DE

9.0
6

Amgen

Biologics and biomanufactured medicines · US

9.0
7

Sartorius

Bioprocessing equipment and lab technologies · DE

8.6
8

GE HealthCare

Medical imaging, patient care and diagnostics · US

8.5
9

Merck

Biopharmaceuticals and vaccines · US

8.4
10

Illumina

Genomic sequencing and array technologies · US

8.4

How we score

  • Impact (30%): scale and weight in the market (revenue, market share, employees, market position).
  • Performance (20%): recent revenue growth and operating margin; an analyst assessment where a company does not publish them.
  • Momentum (20%): growth trajectory and future potential.
  • Innovation (15%): R&D intensity and how technologically advanced the company is.

Popularity (brand search demand, 15%) counts toward Overall but is not published as a column. Overall leaves out what is not known.

Scale Scores are shown on a 7–10 scale with one decimal; bars start at 7.0.

Cadence Recalculated when new figures are published; next review December 11, 2026.

Independence. Rankings are editorially independent. Scores, ranks, picks and the verdict follow the method above; no company can pay to change them.

Cite this ranking

APA

Samuel Norberg. (2026, November 11). Top 10 companies in the bioengineering industry. In Bioengineering Industry Statistics. Gitnux. https://gitnux.org/bioengineering-industry-statistics/#top-companies

report visual · Projection

Domestic business R&D performed in the biotechnology focus area by chemicals manufacturing (United States)

Domestic business R&D performed in the biotechnology focus area by chemicals manufacturing grew from $47.5B in 2018 to $88.6B in 2022.

$47.5B
Start
+16.86%
CAGR · 4y
$88.6B
Projected
20182022
source-verifiedncses.nsf.gov2022

04 Statistics

Technology & Innovation

AI shows mixed maturity: 69% of engineering-biology respondents used AI tools in 2025, but 52% used them only on an ad-hoc basis. Uptake gaps also appear in cloud adoption, with only 17% of respondents at large biopharma companies adopting cloud-based scientific software or SaaS in 2024.

AI in the bioengineering industry

  • 7% of engineering-biology survey respondents reported fully embedded AI tools in 2025, compared with 25% of AI vendors; United Kingdom.[1]
  • 26% of engineering-biology users and vendors were developing AI technologies for genetic engineering in 2025; United Kingdom.[1]
  • 24% of engineering-biology users and vendors were developing AI technologies for drug discovery and development in 2025; United Kingdom.[1]
  • 31% of engineering-biology users and vendors were developing AI technologies for omics-data analysis in 2025; United Kingdom.[1]
  • 69% of engineering-biology survey respondents used AI tools in 2025, while 52% used them only on an ad-hoc basis; United Kingdom.[1]

Automation in the bioengineering industry

  • Only 17% of respondents at large biopharma companies reported adopting cloud-based scientific software or SaaS in 2024; United States and Europe.[2]
  • 37% of respondents at small biopharma companies reported that more than 60% of R&D lab instruments had automated data capture in 2024; United States and Europe.[2]

Digital Transformation in the chemicals and materials sector (sector benchmark)

  • Across European chemical subindustries, 65% of companies viewed digitalization as an opportunity that would significantly impact their activities in 2024.[3]
  • Among ASUG chemicals-industry members, 57% identified moving to SAP S/4HANA as a top focus area in 2025.[4]
  • Among ASUG chemicals-industry members, 46% ranked automation among their leading technology focus areas in 2025.[4]
  • Among EII businesses, 68% reported adopting AI in 2024, with an estimated 10% productivity increase.[3]

Technology Adoption in the chemicals and materials sector (sector benchmark)

  • Among chemicals organizations surveyed by IBM, 53% had implemented AI for real-time process control and optimization in 2025.[5]
  • Among chemicals organizations surveyed by IBM, 49% had implemented AI for production planning and scheduling in 2025.[5]
  • Among chemicals organizations surveyed by IBM, 45% had implemented AI for supply-chain optimization in 2025.[5]
  • Among chemicals organizations surveyed by IBM, 49% had implemented AI for quality inspection or defect detection in 2025.[5]

Cloud Computing in the chemicals and materials sector (sector benchmark)

  • Across chemical-sector companies surveyed by Arthur D. Little and Cefic, 15% planned to migrate to cloud computing in coming years in 2023.[6]
  • Across chemical-sector companies surveyed by Arthur D. Little and Cefic, more than 35% had at least partially migrated to cloud computing in 2023.[6]
  • Among EII businesses, 52% reported increased productivity from cloud computing in 2024, while 46% reported no change.[3]
  • Among EII businesses, 2% reported decreased productivity from cloud computing in 2024.[3]

Big Data in the chemicals and materials sector (sector benchmark)

  • Among EII businesses, 6% reported decreased productivity from big data in 2024.[3]
  • Among ASUG chemicals-industry members, 49% cited gaining actionable insights from data and analytics as a current challenge in 2025.[4]
  • Among EII businesses, 48% reported increased productivity from big data in 2024.[3]
  • Among EII businesses, 44% reported no productivity change from big data in 2024.[3]

IoT in the chemicals and materials sector (sector benchmark)

  • Across European countries, 29% of firms used IoT on average in 2021.[7]
  • Among EII businesses, 44% reported increased productivity from IoT in 2024.[3]
  • Across 23 European countries, close to one-third of manufacturing firms used IoT in 2021.[7]
  • Among EII businesses, 56% reported no productivity change from IoT in 2024.[3]

Innovation in the bioengineering industry

  • €193.7 million was spent on biotechnology R&D in 2024, an increase of 4.9% from 2023; Basque Country, Spain.[8]
  • €3.144 billion was spent on internal biotechnology R&D in 2024, up 14.4% from 2023; Spain.[9]
  • 7.0% was the increase in U.S. bioscience employment from 2021 through 2025, reaching more than 2.31 million workers.[10]

05 Statistics

Data & Analytics

Real-world evidence is treated as a strategy input: 96% of surveyed biopharma companies in 2025 considered real-world data and evidence essential to their organizational strategy. Data-quality limits surface too, with 44% of manufacturers reporting AI-project failures caused by poor data quality in 2025.

Business intelligence in the bioengineering industry

  • 80% of surveyed biopharma executives in 2025 expected generative AI to significantly affect real-world-evidence generation within one year.[11]
  • 96% of surveyed biopharma companies in 2025 considered real-world data and evidence essential to their organizational strategy.[11]
  • 72% of life-sciences companies surveyed in 2025 spent up to 100 days annually matching healthcare-professional data across sources.[12]

Data analytics in the bioengineering industry

  • 75% of surveyed pharma and biotech organizations were using real-world data in drug development in 2024.[13]
  • 62% of surveyed pharma and biotech organizations used genomic information as a real-world-data source in 2024.[13]
  • 55% of biopharma AI adopters used AI in process development, including cell-line development, bioprocessing and formulation design, in 2024.[2]
  • 61% of surveyed pharma and biotech organizations used patient registries as a real-world-data source in 2024.[13]

Data Quality in the chemicals and materials sector (sector benchmark)

  • 44% of companies in the manufacturing survey reported AI-project failures caused by poor data quality in 2025, across surveyed manufacturers.[14]
  • 89% of manufacturers said data use improved their decision-making processes in 2026, across the surveyed manufacturing sector.[15]
  • 49% of supply-management organizations rated their data quality as good or excellent in 2024, based on an Institute for Supply Management survey.[16]
  • 42% of manufacturers had a process to verify manufacturing-data accuracy and quality in 2026, while 51% did not.[15]
  • 80% of manufacturers reported a measured value for their operational data in 2026, across the surveyed manufacturing sector.[15]
  • 67% of supply-management organizations said their data quality was better or significantly better than two years earlier in 2024.[16]

Data Governance in the chemicals and materials sector (sector benchmark)

  • 61% of supply-management organizations had a dedicated data-governance function in 2024, based on a survey of more than 121 respondents.[16]
  • 28% of manufacturers had a data-governance leader in 2026, across the Manufacturing Leadership Council survey.[15]
  • 67% of GCC chemical companies had established performance management or KPIs around digital supply chains in 2022.[17]
  • 52% of global chemical companies had established performance management or KPIs around digital supply chains in 2022.[17]
  • 46% of GCC chemical companies had established common data standards with collaboration partners in 2022.[17]
  • 90% of supply-management organizations agreed or strongly agreed that data governance was necessary in 2024.[16]

KPIs in the bioengineering industry

  • 71% of U.S. biopharmaceutical companies surveyed tracked medical-information contacts through a contact center in 2024.[18]
  • 21% of U.S. biopharmaceutical companies surveyed used sentiment analysis as a medical-information KPI in 2024.[18]
  • 11% of U.S. biopharmaceutical companies surveyed used Net Promoter Score as a medical-information KPI in 2024.[18]

06 Statistics

Strategy & Growth

Capital and partnership activity stays central, with biopharma M&A value reaching $138.9 billion across 113 deals by the third quarter of 2026. Employment momentum also shows up in the U.S., with bioscience employment projected to grow 8% from 2025 to 2035.

Growth in the bioengineering industry

  • The U.S. bioscience industry generated $3.19 trillion in total economic output in 2025.[10]
  • U.S. bioscience business establishments increased 22% from 2021 to more than 156,000 in 2025.[10]
  • EU biotechnology added almost €40 billion to the EU economy, with more than 80% generated by health biotechnology.[19]
  • U.S. bioscience employment increased 7.0% from 2021 to 2025, reaching 2.31 million workers in 2025.[10]
  • EU biotechnology grew more than twice as fast as the overall EU economy over the decade preceding 2024.[19]

Differentiation in the bioengineering industry

  • Biosimilars accounted for more than 40% of FDA biologics license application approvals in both fiscal years 2024 and 2025.[20]
  • 21% of the world’s top biotechnology scientific publications came from the European Union in 2024, comparable with the United States and China.[19]
  • Since 2012, almost 35% of centrally authorised medicines in the European Union were manufactured using biotechnology methods or classified as advanced therapy medicinal products.[19]

Mergers and acquisitions in the bioengineering industry

  • 193 life-sciences mergers and acquisitions totaling $220 billion were recorded through November 30, 2025.[11]
  • Life-sciences M&A deal value reached $123 billion across 183 transactions in 2024.[11]
  • Diagnostics M&A reached $42 billion in 2025, driven by spatial multi-omics, AI clinical bioinformatics and scalable molecular diagnostics.[11]
  • Life-sciences M&A investment totaled $130 billion in 2024, down 41% from $222 billion in 2023.[21]
  • Six public biotech or pharmaceutical acquisitions valued at $1 billion or more were completed in 2024.[22]

Strategic partnerships in the bioengineering industry

  • Aggregate therapeutic in-licensing deal value involving Chinese-originated assets rose from $45 billion in 2024 to $105 billion in 2025.[23]
  • Biopharma alliance deal value totaled $192 billion in 2024, according to Citeline and Evaluate data.[10]
  • 51% of 2024 biopharma deals targeted pre-Phase III assets, reflecting increased partnering and dealmaking around earlier-stage innovation.[21]
  • Biopharma alliance deal value totaled $179 billion in 2020, according to Citeline and Evaluate data.[10]
  • More than 330 life-sciences AI partnerships generated over $55 billion in potential deal value during the five years through 2024.[21]

07 Statistics

People & Workforce

Workforce signals reflect a shift toward hybrid arrangements: across U.S. hybrid employees, 48% said their team had not discussed a formal or informal collaboration plan in 2026, and hybrid employees spent an average of 46% of their workweek on-site in 2026.

Hiring in the bioengineering industry

  • 2.9 million unique U.S. life-sciences job postings were analyzed for workforce trends covering the four years through early 2025.[24]
  • 152,000 bioscience jobs were added in the United States from 2021 through 2025, bringing industry employment above 2.31 million workers.[10]
  • More than 200 life-sciences industry executives across 22 states and Puerto Rico were interviewed on hiring and talent dynamics from late 2024 through early 2025.[24]
  • 0.3% was the contraction in U.S. life-sciences employment in 2024, according to an analysis of industry workforce trends.[24]

Employee retention in the bioengineering industry

  • 15% was the average employee turnover rate at North Carolina biopharmaceutical manufacturing sites in 2021.[25]
  • 13% was the average employee turnover rate at North Carolina biologics manufacturing sites in 2021.[25]

Remote Work in the chemicals and materials sector (sector benchmark)

  • Among U.S. energy, natural-resources and chemicals workers, 8% preferred fully remote work in 2025.[26]
  • Among U.S. energy, natural-resources and chemicals workers, 25% preferred mostly remote work in 2025.[26]
  • Across U.S. remote-capable employees, 25% worked exclusively remotely in August 2026.[27]
  • Across U.S. chemical and pharmaceutical manufacturing employers, 5.7% of positions were fully remote in 2024.[28]

Hybrid Work in the chemicals and materials sector (sector benchmark)

  • Across U.S. chemical and pharmaceutical manufacturing employers, 44.5% of positions were fully hybrid in 2024.[28]
  • Across U.S. remote-capable employees, 61% preferred a hybrid work arrangement in November 2025.[27]
  • Across U.S. hybrid employees, 48% said their team had not discussed a formal or informal collaboration plan in 2026.[27]
  • Across U.S. remote-capable employees, 54% worked in a hybrid arrangement in August 2026.[27]
  • U.S. hybrid employees spent an average of 46% of their workweek on-site in 2026.[27]

Upskilling in the bioengineering industry

  • 77% of life-sciences training respondents sought training for their current role in 2024; the sample covered biopharmaceutical, cell-and-gene-therapy and medical-device professionals.[29]
  • 64% of UK biopharma job postings mentioned physical and inherent abilities such as leadership and problem-solving, according to analysis through 2023.[30]
  • 65% of UK biopharma job postings mentioned business-related skills, according to analysis of industry postings through 2023.[30]
  • 57% of UK biopharma job postings mentioned media and communication skills, according to analysis of industry postings through 2023.[30]

Employee Engagement in the chemicals and materials sector (sector benchmark)

  • Across employees in the United States and Canada, 31% were engaged at work in 2025.[27]
  • Among global managers, 22% were engaged at work in 2025, compared with 19% of non-managers.[27]
  • Across best-practice organizations recognized by Gallup, 70% of employees were engaged in 2025.[27]
  • Across employees worldwide, 20% were engaged at work in 2025.[27]
  • Across employees in the United States, 32% were engaged at work in 2025.[27]

DEI in the bioengineering industry

  • 79% of participating biotechnology companies had active partnerships with diverse educational institutions or community and professional organizations in 2024.[31]
  • 69% of participating biotechnology companies collected race-and-ethnicity information in HR systems in 2024; BIO-member companies.[31]
  • 85% of participating biotechnology companies rated DEI an important, very important or critical strategic focus in 2024; BIO-member companies.[31]
  • 85% of participating biotechnology companies collected employee-gender information in HR systems in 2024; BIO-member companies.[31]
  • 90% of participating biotechnology companies collected employee-age information in HR systems in 2024; BIO-member companies.[31]

Change Management in the chemicals and materials sector (sector benchmark)

  • Across leaders in the United States, United Kingdom, Australia and Canada, change management was associated with a reported 4:1 return on investment in 2026.[11]

08 Statistics

Marketing & Brand

Buyer-facing acquisition channels remain concentrated on digital properties and events: 64% of life-sciences executives rated direct brand websites as important, and 84% rated in-person events, conferences and tradeshows as important. AI is also used in marketing tasks by 52% of surveyed life-science companies in 2024.

Marketing in the bioengineering industry

  • 64% of life-sciences executives rated direct brand websites as important customer-acquisition channels.[32]
  • 61% of life-science companies contracted work through an external marketing agency in 2024, down from 71% in 2023.[33]
  • 84% of life-sciences executives rated in-person events, conferences and tradeshows as important customer-acquisition channels.[32]
  • 52% of surveyed life-science companies used artificial intelligence for marketing tasks in 2024.[33]

Digital marketing in the bioengineering industry

  • More than 90% of surveyed medical-technology companies reported that digital-marketing success improved by at least 10%.[34]
  • 40% of surveyed medical-technology companies said social-media campaigns were the most effective digital channel for generating new launch opportunities.[34]
  • 50% of U.S. medical-technology respondents reported digital-marketing return on investment of at least 20%.[34]
  • 45% of surveyed medical-technology companies said email campaigns were the most effective digital channel for generating new opportunities during product launches.[34]

Branding in the bioengineering industry

  • 68% of life-sciences executives rated industry-analyst relations as important for customer acquisition.[32]
  • 79% of life-sciences executives rated referrals as important for customer acquisition, while 45% rated them effective at personalization.[32]
  • 74% of life-sciences executives rated professional associations as important customer-acquisition channels.[32]
  • 64% of life-sciences executives rated a direct brand website as an important customer-acquisition channel, while 36% rated it effective at personalization.[32]

Social media in the bioengineering industry

  • 25% of life-science sponsors outsourced social-media activity in 2024.[33]
  • 40% of biopharmaceutical companies outsourced social-media activity in 2024, compared with 10% of medical-technology companies.[33]
  • LinkedIn received an average rating of 4.47 out of 5 as a social-media platform among drug-development-service companies.[33]
  • 26% of drug-development-service companies outsourced some or all social-media activity in 2024, up from 13% in 2020.[33]

Influencer Marketing in the chemicals and materials sector (sector benchmark)

  • Across B2B companies, 43% of marketers reported outstanding results from influencer programs in the 2025 B2B Influencer Marketing Report.[35]
  • Across B2B companies, 81% of marketers had a dedicated influencer-marketing budget in a September 2024 U.S. survey of firms with at least 100 employees.[36]
  • Across B2B companies, 29% of marketers planned to adopt influencer marketing within the following year in a March 2025 Ipsos survey.[37]
  • In U.S. manufacturing, 19% of marketers used influencer marketing among paid channels in the prior 12 months, according to a 2025 industry benchmark.[38]
  • Across B2B companies, 55% of marketers used creators in 2025, based on a March 2025 Ipsos survey of 1,500 marketing professionals.[37]

09 Statistics

Operations & Execution

Manufacturing execution and data use are tied to optimization and quality monitoring: 46% of life-sciences manufacturers used collected industrial data for process optimization in 2025, and 38% used collected data to improve or monitor product quality in the same survey.

Process optimization in the bioengineering industry

  • 33% of biopharma supply-chain leaders said their organizations planned to scale digital capabilities such as digital twins and machine vision for process improvements within five years.[11]
  • 38% of life-sciences manufacturers used collected data for production planning or scheduling in the 2025 survey.[39]
  • 46% of life-sciences manufacturers used collected industrial data for process optimization in the 2025 smart-manufacturing survey.[39]
  • 38% of life-sciences manufacturers used collected data to improve or monitor product quality in the 2025 survey.[39]

Operational efficiency in the bioengineering industry

  • 47% of medtech executives said deploying generative or agentic artificial intelligence would be a primary cost-containment strategy in 2026.[11]
  • 31% of biopharma executives said deploying generative or agentic artificial intelligence would be a primary cost-management strategy in 2026.[11]
  • 30% of medtech executives said improving research-and-development or product-development productivity would be a primary cost-management strategy in 2026.[11]
  • 41% of biopharma executives said improving research-and-development or product-development productivity would be a primary cost-management strategy in 2026.[11]

Quality management in the bioengineering industry

  • 14.1% of global biopharmaceutical manufacturing respondents reported a batch failure within the previous one to three months.[40]
  • 21% of biopharma respondents ranked price as the number-one factor in selecting a contract-development-and-manufacturing organization in 2024.[41]
  • 36.5% of global biopharmaceutical manufacturing respondents reported that their facility’s last batch failure occurred at least two years earlier.[40]
  • 67% of biopharma respondents ranked quality as the number-one factor in selecting a contract-development-and-manufacturing organization in 2024.[41]

Supply chain in the bioengineering industry

  • 48% of biopharma supply-chain leaders reported improved warehouse efficiency from digitalization in 2023.[11]
  • 50% of biopharma supply-chain leaders reported improved yields from digitalization in 2023.[11]
  • 47% of biopharma supply-chain leaders reported improved cost-effective sourcing from digitalization in 2023.[11]
  • 50% of biopharma supply-chain leaders reported improved risk-sensing from digitalization in 2023.[11]

Outsourcing / Offshoring in the chemicals and materials sector (sector benchmark)

  • Across North American specialty chemicals, 100% of customer respondents allocated only 0–25% of company capital expenditure to reshoring projects in 2025.[42]
  • Across North American specialty chemicals, 50% of customer respondents actively drove onshoring projects with suppliers but reported no success in 2025.[42]
  • Across 22 EU countries and Norway, 72.8% of enterprises engaged in international sourcing moved business functions to other EU countries during 2021–2023.[43]
  • Across North American specialty chemicals, 50% of customer respondents were actively pushing onshoring projects in 2025.[42]
  • Across 22 EU countries and Norway, 34.1% of enterprises engaged in international sourcing cited labour-cost reduction as a motivation during 2021–2023.[43]

10 Statistics

Finance & Pricing

Cost management actions include pricing and access strategy: 29% of biopharma executives said optimizing pricing, reimbursement and access strategies would be a primary cost-management action in 2026. Ecosystem participation also connects to cost and incremental growth, with 13.7% of annual revenue attributed to cost reductions.

Pricing strategy in the bioengineering industry

  • 29% of biopharma executives said optimizing pricing, reimbursement and access strategies would be a primary cost-management action in 2026.[11]
  • Biopharma acquiring firms collectively generated $23 billion more revenue during the two years after acquisitions while reducing physician-detailing spending by $1.19 billion.[44]
  • 37% of medtech executives said optimizing pricing, reimbursement and access strategies would be a primary cost-management action in 2026.[11]
  • 54% of acquired branded drugs in a study of 73 biopharma mergers and acquisitions followed an extract strategy combining higher prices with lower promotional spending.[44]

Cost reduction in the bioengineering industry

  • 40% of biopharma executives said cost-cutting compromises product quality, according to the 2025 Global Biopharma Index.[45]
  • 31% of life-sciences companies said cost reduction was the main benefit of co-sourcing multinational tax compliance and statutory reporting.[21]
  • 87% of life-sciences companies planned to reduce tax-and-finance budgets, by an average of 5.4%.[21]
  • 13.7% of life-sciences companies’ total annual revenue was attributed to cost reductions from ecosystem participation in EY’s ecosystem study.[46]

Profitability in the bioengineering industry

  • 22.9% was the average earnings-before-interest-and-tax margin for the 20 largest pharmaceutical multinational enterprises in 2020.[47]
  • 28.6% of revenue was the average marketing, sales and general-expense ratio for the 20 largest pharmaceutical multinational enterprises in 2020.[47]
  • 20.0% of revenue was the average research-and-development cost for the 20 largest pharmaceutical multinational enterprises in 2020.[47]
  • 28.5% of revenue was the average cost-of-goods-sold ratio for the 20 largest pharmaceutical multinational enterprises in 2020.[47]

Financial planning in the bioengineering industry

  • $10.6 million was the estimated average five-year spending on tax technology among surveyed life-sciences companies.[21]
  • 82% of life-sciences companies were more likely than not to co-source selected tax-and-finance activities within the following 24 months.[21]
  • 14.4% of life-sciences companies’ incremental earnings were attributed to ecosystem participation in EY’s ecosystem study.[46]
  • 14.1% of life-sciences companies’ incremental revenue growth was attributed to ecosystem participation in EY’s ecosystem study.[46]

11 Statistics

Product & Service

Innovation and compliance are framed as success measures: 31% of biotech survey respondents in 2024 cited compliance performance as a measure of success, and 18.5% was the R&D intensity of U.S. pharmaceutical and medicine manufacturing companies in 2024.

Product development in the bioengineering industry

  • 39% of global biotechnology patents originated in the United States in 2020, compared with 18% in the European Union and 10% in China.[48]
  • 22.2% of U.S. scientific research and development services companies introduced a product innovation during 2018–2020.[49]
  • 18.5% was the R&D intensity of U.S. pharmaceutical and medicine manufacturing companies in 2024.[49]
  • 8% growth is projected for U.S. bioengineer and biomedical-engineer employment between 2025 and 2035.[50]

Value proposition in the bioengineering industry

  • 31% of biotech survey respondents in 2024 cited compliance performance as a measure of success.[51]
  • 30% of biotech survey respondents in 2024 cited profitability as a measure of success.[51]
  • 41% of biotech survey respondents in 2024 cited the opportunity to sell or divest a product or associated business as a measure of success.[51]
  • 33% of biotech survey respondents in 2024 cited partner or investor interest as a measure of success.[51]

12 Statistics

Sustainability & Ethics

Sustainability reporting shows frequent greenhouse-gas actions: 77% of 86 European biotechnology and pharmaceutical companies initiated steps to reduce greenhouse-gas emissions in 2023, and 35% had quantitative greenhouse-gas-reduction targets in 2024.

Sustainability in the bioengineering industry

  • 50% of surveyed Belgian biopharmaceutical companies had started carbon-reduction initiatives, according to 2024 reporting.[52]
  • 72% of surveyed corporate executives said biosolutions could significantly accelerate progress toward sustainability goals in 2024.[53]
  • 49% of 86 European biotechnology and pharmaceutical companies had implemented water-management measures in 2023.[54]
  • 77% of 86 European biotechnology and pharmaceutical companies had initiated steps to reduce greenhouse-gas emissions in 2023.[54]

ESG in the bioengineering industry

  • 35% of 86 European biotechnology and pharmaceutical companies had quantitative greenhouse-gas-reduction targets in 2024.[55]
  • 70% of 86 European biotechnology and pharmaceutical companies scored between 31 and 70 points on a 0–100 ESG scale in 2024.[55]
  • 9% of 86 European biotechnology and pharmaceutical companies had greenhouse-gas targets validated by the Science Based Targets initiative in 2024.[55]
  • 52% of 86 European biotechnology and pharmaceutical companies reported Scope 3 emissions in 2024.[55]

CSR in the bioengineering industry

  • Approximately two-thirds of surveyed Belgian biopharmaceutical companies had a dedicated ESG employee in 2024.[52]
  • 25% of surveyed Belgian biopharmaceutical companies had begun calculating emissions in 2024.[52]
  • More than half of surveyed Belgian biopharmaceutical companies said sustainability played a significant role in securing capital financing in 2024.[52]

Carbon footprint in the bioengineering industry

  • More than four-fifths of the biotechnology and pharmaceutical industry’s carbon footprint came from Scope 3 emissions in the 2023 data analyzed by EthiFinance.[55]
  • 25 top biopharmaceutical companies reduced their carbon impact according to the industry analysis released at COP28.[56]

14 Statistics

Globalization & Expansion

Foreign investment flows remain location-skewed: 31% of global biotechnology foreign-direct-investment projects attracted by location between 2003 and 2024 went to the United States, compared with 28% to European Union member states.

Globalization in the bioengineering industry

  • 31% of global biotechnology foreign-direct-investment projects attracted by location between 2003 and 2024 went to the United States.[7]
  • 28% of global biotechnology foreign-direct-investment projects between 2003 and 2024 went to European Union member states.[7]
  • The European Economic Area’s share of global commercial clinical trials fell from 22% in 2013 to 12% in 2023.[19]
  • 66 of 67 European Union biotechnology firms that listed during 2019–2025 chose non-EU stock exchanges.[19]
  • 13% of global biotechnology foreign-direct-investment projects between 2003 and 2024 went to China.[7]

Distribution channels in the bioengineering industry

  • Bioscience-related distribution was among the U.S. bioscience subsectors that continued adding jobs in 2025.[10]
  • Bioscience-related distribution employed part of the 2.31 million people working in the U.S. bioscience industry in 2025.[10]
  • More than 156,000 bioscience business establishments operated across all 50 U.S. states, the District of Columbia and Puerto Rico in 2025.[10]

Key questions about the bioengineering industry

What was the global bioengineering market size in 2025?
The global bioengineering market was estimated at $295.88 billion in 2025.
How fast is the market projected to grow from 2026 to 2033?
The market is projected to reach $1.479 trillion by 2033, representing a 17.53% compound annual growth rate from 2026 to 2033.
Which companies lead the bioengineering industry?
Eli Lilly and Company stands out for biopharmaceutical medicines and biologics because it recorded revenue growth of 44.7% and an operating margin of 40.4% in 2025, while Boston Scientific focuses on minimally invasive devices since it makes devices for cardiovascular, endoscopy, urology and other fields with revenue growth of 19.9% in 2025.
What technology shifts show up in 2025 adoption and development data?
In 2025, 69% of engineering-biology survey respondents used AI tools, and 52% used them only on an ad-hoc basis. Separately, 80% of surveyed biopharma executives expected generative AI to significantly affect real-world-evidence generation within one year.
How concentrated is deal activity in bioengineering-related life-sciences transactions?
In 2025, the average life-sciences deal size was approximately $2.7 billion, and the first quarter represented 36% of the year's $99.7 billion total tracked by EY.
What regulatory activity levels were reported for biologics and biosimilars in 2025?
In 2025, the FDA approved 46 novel drugs, including 12 biologics, and approved 18 biosimilars for 10 reference products. The agency also reported 87 Breakthrough Therapy designations in its Biologics Program by the end of fiscal 2025.
Reference

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA
Samuel Norberg. (2026, November 11). Bioengineering Industry Statistics. Gitnux. https://gitnux.org/bioengineering-industry-statistics
MLA
Samuel Norberg. "Bioengineering Industry Statistics." Gitnux, 11 Nov 2026, https://gitnux.org/bioengineering-industry-statistics.
Chicago
Samuel Norberg. 2026. "Bioengineering Industry Statistics." Gitnux. https://gitnux.org/bioengineering-industry-statistics.

Sources & references

76 sources cited across this report

  1. gov.uk
  2. benchling.com
  3. monitor-industrial-ecosystems.ec.europa.eu
  4. s3.us-east-1.amazonaws.com
  5. ibm.com
  6. cefic.org
  7. oecd.org
  8. en.eustat.eus
  9. ine.es
  10. bio.org
  11. deloitte.com
  12. pharmalive.com
  13. emjreviews.com
  14. dnb.com
  15. manufacturingleadershipcouncil.com
  16. utah.ismworld.org
  17. gpca.org.ae
  18. link.springer.com
  19. health.ec.europa.eu
  20. fda.gov
  21. ey.com
  22. ropesgray.com
  23. iqvia.com
  24. bioutah.org
  25. ncbiotech.org
  26. kpmg.com
  27. gallup.com
  28. naceweb.org
  29. educolifesciences.com
  30. abpi.org.uk
  31. dev.bio.org
  32. business.adobe.com
  33. scorrmarketing.com
  34. mckinsey.com
  35. toprankmarketing.com
  36. marketingprofs.com
  37. business.linkedin.com
  38. contentmarketinginstitute.com
  39. cphi-online.com
  40. img.pharmamanufacturing.com
  41. ir.fujifilm.com
  42. 5418442.fs1.hubspotusercontent-na1.net
  43. ec.europa.eu
  44. ama.org
  45. pharmamanufacturing.com
  46. assets.ey.com
  47. ptpsi.com
  48. joint-research-centre.ec.europa.eu
  49. ncses.nsf.gov
  50. bls.gov
  51. arriello.com
  52. pharma.be
  53. capgemini.com
  54. static.seitosei-presse.com
  55. ethifinance.com
  56. nature.com
  57. enhesa.com
  58. ismg-cdn.nyc3.cdn.digitaloceanspaces.com
  59. trustarc.com
  60. chemtrec.com
  61. claritasintelligence.com
  62. jpmorgan.com
  63. lilly.com
  64. bostonscientific.com
  65. roche.com
  66. annualreport.novonordisk.com
  67. siemens-healthineers.com
  68. amgen.com
  69. sartorius.com
  70. investor.gehealthcare.com
  71. merck.com
  72. illumina.com
  73. ema.europa.eu
  74. genome.gov
  75. who.int
  76. cdn.who.int